# Integrated tumor genomic and immune microenvironment

## Metadata

```yaml
---
paper_id: "integrated_genomic_immune_tme"
title: "Integrated tumor genomic and immune microenvironment"
authors: "UNKNOWN — pending OCR"
year: UNKNOWN — pending OCR
venue: "UNKNOWN — pending OCR"
paper_type: "UNKNOWN — pending OCR (likely review or primary research on genomic–immune integration in breast cancer, inferred from title only)"
domain: "A_Genomic_Signal"
subdomain: "integrated tumor genomics + immune microenvironment"
relevance_score: 4
priority_level: "HIGH"
corpus_role: "reference"
temporal_status: "active_candidate"
relevance_tags:
  - "immune_microenvironment"
  - "TILs"
  - "tumor_infiltrating_lymphocytes"
  - "genomic_drivers"
  - "WES"
  - "integrative_genomics"
  - "immune_gene_signatures"
  - "TNBC"
  - "HER2_positive"
  - "neoadjuvant_response"
  - "pCR"
  - "OCR_pending"
doi: ""
isbn: ""
url: ""
pdf_file: "integrated_genomic_immune_tme.pdf"
---
```

---

## One-Sentence Summary

**OCR REQUIRED — scanned image PDF, no text layer.** Based on title and project placement only: this source appears to address how tumor genomic features (somatic drivers, mutational burden, immune-related genomic alterations) relate to the immune tumor microenvironment in breast cancer — a framing directly relevant to AQ-1 and AQ-3 for WES-derived immune-linked driver prioritization, but no body content has been verified until OCR is completed.

---

## Key Contributions

> **All items below are inferred from title and corpus placement only — not verified against the document body. Revisit after OCR.**

- Likely synthesizes or reports **links between tumor genomic profiles and immune microenvironment features** (e.g., infiltration, immune gene expression, antigen presentation, immune escape mechanisms) in breast cancer.
- Expected to sit at the **A3 (immune microenvironment) ∩ A4 (genomic drivers)** interface — relevant for classifying which WES-observable alterations co-occur with or mechanistically shape immune context.
- Potentially supports **AQ-3 gene prioritization** by distinguishing immune-relevant genomic drivers from background mutation noise when immune context is integrated.
- May bridge toward **B3 (immunotherapy)** therapeutic context once body content is extractable.

---

## Core Idea / Mechanism / Argument

> **Content not extractable.** The co-located PDF (`integrated_genomic_immune_tme.pdf`) is a 13-page scanned image document with no selectable text layer. Read-tool inspection and attempted shell extraction returned only page markers (`-- N of 13 --`).

### What can be stated without fabrication

From the **title alone**, the source is positioned in the literature space of **integrating tumor genomics with immune microenvironment biology** — a well-established axis in breast cancer neoadjuvant response research where:

1. **Genomic layer** — somatic mutations, copy-number changes, mutational signatures, neoantigen burden, HLA loss, and driver alterations observable from WES.
2. **Immune microenvironment layer** — TIL density, immune cell composition, cytotoxic/exhaustion signatures, stromal immune exclusion, and related TME phenotypes.
3. **Integration claim space** — how genomic features predict, correlate with, or mechanistically influence immune infiltration and anti-tumor immunity, and whether that integration improves treatment-response stratification.

**Claimed vs demonstrated:** Cannot be assessed until OCR. Do not cite this entry as evidence for any specific gene, effect size, or mechanism.

---

## Methodology / Evidence Base

> **Pending OCR.** The following fields cannot be filled without body text.

### If empirical (unknown until OCR)
- **Design**: UNKNOWN
- **Sample / setting**: UNKNOWN
- **Measurements / instruments**: UNKNOWN
- **Statistical analysis approach**: UNKNOWN

### If review / synthesis (unknown until OCR)
- **Theoretical framework invoked**: UNKNOWN
- **Sources drawn upon**: UNKNOWN

---

## Relationship with the project's goals

### Which corpus scope and anchor question(s) this source engages with

- **Corpus**: `A_Genomic_Signal` — category `A3_Immune_Microenvironment` (primary); bridges `A4_Genomic_Landscape_Drivers_CNV_SV` (genomic drivers).
- **Anchor question(s)**: **AQ-1** (WES mutational drivers correlated with pCR); **AQ-3** (high-priority drivers vs genomic background noise).
- **Bridge corpus**: **A4** (genomic drivers/CNV/SV); **B_Therapeutic_Context → B3** (immunotherapy / checkpoint context).

### How it could be used

- **Directly reusable**: *Pending OCR* — if the body catalogs immune-linked genomic drivers, co-alteration patterns, or integrative biomarkers tied to neoadjuvant response in TNBC/HER2+ breast cancer, it could feed the candidate-gene shortlist.
- **Indirectly inspiring**: Even as an unprocessed reference, the title signals a **genomics–TME integration frame** that aligns with multi-omic predictors (e.g., `sammut_2022_multiomic_ml`) and immune-axis prioritization in the project.
- **Mainly background / framing**: Until OCR, treat as a **placeholder index entry** marking a priority A3 source whose exact claims remain unverified.

### Main fit with the project

- **A3 is a project priority axis** (`project_overview.md` §6): immune microenvironment biology carries established treatment-linked pCR biomarkers in breast cancer.
- Integrating **WES-derived genomic signal with immune context** is central to separating predictive drivers (AQ-1) from noise (AQ-3) when immune engagement modulates response to neoadjuvant chemotherapy ± anti-HER2 ± immunotherapy.

### Main mismatch or risk

- **No verified content yet** — any specific gene list, cohort, endpoint, or effect size would be fabricated if stated now.
- Title-level inference does not confirm **breast-cancer-only scope**, **pCR endpoint**, or **WES platform** — these must be checked after OCR against project boundaries (`project_overview.md` §5).

### Concrete follow-up

1. **Run OCR** on `integrated_genomic_immune_tme.pdf` (13 pages, image-only).
2. After OCR: extract authors, year, venue, paper type; fill methodology, results, and 5–10 body quotes.
3. Re-evaluate `corpus_role` — promote to `decision` if the body provides actionable WES+immune driver evidence for TNBC/HER2+ neoadjuvant pCR.
4. Update `CROSS_REFERENCE_INDEX.md` and `README.md` registry with verified metadata.

---

## Assumptions

- The filename/title accurately reflects the document's subject (integrated tumor genomics and immune microenvironment).
- The 13-page PDF is complete and legible enough for OCR.
- **Not assumed**: specific authorship, publication year, journal, breast-cancer focus, pCR endpoint, or any quantitative findings — all pending OCR.

---

## Limitations / Failure Modes

- **OCR REQUIRED — scanned image PDF, no text layer.** The source cannot be searched, quoted, or deep-ingested until text is recovered. All structured fields beyond title-level inference are provisional.
- **Extraction attempts (2025-06-18)**: `pdftotext` not installed on host; `python`/`py` not available; Read-tool PDF view confirms image-only pages with no extractable text.
- **Reference-only status**: This entry must not be used as primary evidence for gene prioritization, effect sizes, or mechanistic claims.
- **Risk of misclassification**: Without body text, paper type (review vs primary cohort vs method) and endpoint (pCR vs survival vs immune infiltration alone) are unknown — may require re-categorization after OCR.

---

## Key Quantitative or Qualitative Results

> **Not available — pending OCR.** Do not infer numbers, sample sizes, p-values, or gene-level effect sizes from this entry.

---

## Key Quotes

> **Not available — pending OCR.** Direct body quotes cannot be included without fabricated content. Revisit after OCR (target: 5–10 quotes grounding mechanisms, claims, or limitations).

---

## Cross-References

### Complements entries in corpus
- `sammut_2022_multiomic_ml`: Multi-omic ML integration of WES DNA features (TMB, HRD, TP53, PIK3CA, HLA LOH) with immune/transcriptomic layers for pCR prediction — likely the closest validated benchmark once this source is readable.
- `davies_2017_hrdetect`, `telli_2016_hrd_score`: DNA-repair/HRD genomic signals that may co-segregate with immune context in integrative frameworks.

### Contradicts / Tensions
- _(none identifiable until OCR)_

### Cross-corpus connections
- **A4** (`A_Genomic_Signal`): Genomic drivers and CNV/SV landscape that may shape antigen presentation and immune visibility.
- **B3** (`B_Therapeutic_Context`): Immunotherapy/checkpoint context — immune TME genomic integration often maps to IO-responsive vs IO-excluded phenotypes.
- **D** (`D_Clinical_Endpoint`): Verify whether body ties integration claims to **pCR** (in scope) vs survival/resistance only (supporting context).

### Related entries to add
- **HIGH**: Any primary TNBC/HER2+ neoadjuvant cohort papers cited inside this document once OCR reveals the reference list.
- **MEDIUM**: Immune gene signatures derivable from WES-adjacent data (RNA required) if the source discusses transcriptomic immune deconvolution.

---

## Author Notes

### Priority justification
- **HIGH** because A3 (immune microenvironment) is a **project priority axis** and this title explicitly targets **genomic–immune integration** — the intersection most relevant to AQ-1/AQ-3 WES driver prioritization with immune context.
- Held at `reference` (not `decision`) solely because the body is unreadable; priority may increase after OCR.

### Use this source for
- Locating the physical PDF pending OCR processing.
- Indexing the **genomics + immune TME integration** topic within A3.
- Flagging a priority follow-up for deep ingestion once text is recoverable.

### Do NOT use this source for
- Citing specific genes, mutations, immune signatures, cohort statistics, or treatment outcomes → **requires OCR first**.
- Primary support in ideation or gene shortlisting → use `sammut_2022_multiomic_ml` or other verified `decision` entries until this source is upgraded.

### Curation notes

> **⚠ OCR REQUIRED — scanned image PDF, no text layer**

- Source file: `Doc/Doc_brute/Integrated tumor genomic and immune microenvironment.pdf` (13 pages; image-only).
- Canonical copy: `integrated_genomic_immune_tme.pdf` (co-located with this entry).
- **Authors, year, venue**: UNKNOWN — pending OCR.
- **Extraction log**: `pdftotext` unavailable; Python/pypdf unavailable; Read tool confirms no text layer.
- **Index updates deferred**: `CROSS_REFERENCE_INDEX.md` and `README.md` registry updates should be applied after OCR confirms content (suggested additions documented below for parent agent).
- After OCR: harmonize immune terminology (TILs, immune infiltration, cytolytic activity, TIDE, IPS, etc.) with existing A3 index rows.

---

## Related Concepts

- immune microenvironment (TME)
- tumor-infiltrating lymphocytes (TILs)
- integrative genomics
- somatic drivers (WES)
- tumor mutational burden (TMB)
- neoantigens / HLA
- immune gene expression signatures
- immune exclusion / evasion
- neoadjuvant response / pCR
- TNBC / HER2+ breast cancer
- genomics–immunology bridge

---

## Quality Checklist

- [x] precise terminology of the discipline is used throughout (where not blocked by OCR)
- [x] the source-type contextualization in Author Notes is complete
- [x] assumptions are explicit
- [x] novel contributions are distinguished from inherited components (marked as unverified)
- [ ] quantitative or qualitative results include the relevant specifics — **blocked: OCR required**
- [ ] at least 5 useful direct quotes are included — **blocked: OCR required**
- [x] cross-references are present (including cross-corpus when relevant)
- [x] the project-relevance relationship section is complete
- [ ] the relevant `CROSS_REFERENCE_INDEX.md` has been updated — **deferred pending OCR (per ingestion constraints)**
- [ ] the corpus `README.md` registry and counts have been updated — **deferred pending OCR (per ingestion constraints)**
